Safety, pharmacokinetic and pharmacodynamic profiles of split-dose of tolvaptan in patients with autosomal dominat polycystic kidney disease with preserved renal function (Trial 249)

Trial Profile

Safety, pharmacokinetic and pharmacodynamic profiles of split-dose of tolvaptan in patients with autosomal dominat polycystic kidney disease with preserved renal function (Trial 249)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 27 Feb 2017 New trial record
    • 20 Feb 2017 Results of three phase II studies published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top